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MyoD is a key regulator of skeletal myogenesis that
directs contractile protein synthesis, but whether
this transcription factor also regulates skeletal
muscle metabolism has not been explored. In a
genome-wide ChIP-seq analysis of skeletal muscle
cells, we unexpectedly observed that MyoD directly
binds to numerous metabolic genes, including those
associated with mitochondrial biogenesis, fatty acid
oxidation, and the electron transport chain. Results
in cultured cells and adult skeletal muscle confirmed
that MyoD regulates oxidative metabolism through
multiple transcriptional targets, including PGC-1b, a
master regulator of mitochondrial biogenesis. We
find that PGC-1b expression is cooperatively regu-
lated by MyoD and the alternative NF-kB signaling
pathway. Bioinformatics evidence suggests that
this cooperativity betweenMyoD and NF-kB extends
to other metabolic genes as well. Together, these
data identify MyoD as a regulator of the metabolic
capacity of mature skeletal muscle to ensure that
sufficient energy is available to support muscle
contraction.
INTRODUCTION
Skeletal myogenesis involves the fusion of proliferating myo-
blasts into multinucleated, contractile myotubes (Bentzinger
et al., 2012). At the molecular level, myogenic differentiation is
controlled through a highly conserved family of skeletal muscle
specific transcription factors including MyoD, Myf5, myogenin,
and MRF4 (Comai and Tajbakhsh, 2014). These factors function
as heterodimers with E protein subunits that bind to E box
consensus sites within promoters and enhancers of genes
involved in proliferation, migration, fusion, and contraction
(Bergstrom et al., 2002; Gong et al., 2015; Tajbakhsh et al.,514 Cell Reports 17, 514–526, October 4, 2016 ª 2016 The Authors.
This is an open access article under the CC BY-NC-ND license (http://1996). MyoD in particular is important for postnatal myoblasts
to progress through differentiation to form adult skeletal muscle
(Cornelison et al., 2000; Sabourin et al., 1999).
Asmyoblasts differentiate, MyoD binding increases on amulti-
tude of genes, including those that form the contractile appa-
ratus (Cao et al., 2010). Studies performed on the myosin heavy
chain, skeletal a-actin, and troponin promoters demonstrated
that MyoD can mediate transcriptional activation of these myofi-
brillar genes through its recruitment of chromatin remodeling
factors (Groisman et al., 1996; Polesskaya et al., 2001; Puri
et al., 1997). Expression of these genes is vital to the develop-
ment and maintenance of myofiber contractile function. Consis-
tent with this requirement, the absence ofMyoD inmiceweakens
muscle contraction (Staib et al., 2002).
In addition to the development of contractile structures, myo-
genesis is associated with a shift in metabolism from glycolysis
to oxidative phosphorylation, including a corresponding in-
crease inmitochondrial biogenesis (Kraft et al., 2006). This meta-
bolic shift is presumably required to synthesize the large pool of
ATP needed to sustain the energy demands of contracting mus-
cle. Members of the PPARg coactivator-1 (PGC-1) family, mainly
PGC-1a and PGC-1b, interact with and stimulate the transacti-
vation functions of NRF-1, NRF-2, PPARa, PPARd, and ERRa
to enhance mitochondrial content and the oxidative capacity of
muscle (Arany, 2008). Consequently, transgenic expression of
either PGC-1a or PGC-1b in myofibers increases mitochondrial
biogenesis and oxidative phosphorylation (Arany et al., 2007;
Lin et al., 2002b).
Our laboratory recently implicated the alternative NF-kB
signaling pathway in the regulation of PGC-1b transcription
(Bakkar et al., 2012). In contrast to canonical NF-kB signaling,
the alternative pathway is regulated by an IkB kinase a (IKKa) ho-
modimer complex, which phosphorylates the p100 precursor
protein, resulting in its partial proteolysis and formation of the
mature p52 subunit of NF-kB (Oeckinghaus et al., 2011). The
p52 subunit forms a heterodimer with RelB, which then translo-
cates to the nucleus to bind NF-kB consensus binding sites and
stimulate transcription. We found that RelB binds within the first
intron of the PGC-1b gene, which is sufficient to activate PGC-1bcreativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. MyoD Binds to a Network of Meta-
bolic Genes
(A) MyoD ChIP-seq using C2C12 myotubes was
annotated followed by gene ontology analysis
using HOMER. The top 10 biological processes
are listed, with categories related to metabolism
listed in dark blue.
(B) Selected biological processes and cellular
components related to mitochondrial biogenesis
and function are listed.
(C) MyoD ChIP-seq peaks are visualized on
selected genes with functions related to oxidative
metabolism.
See also Figure S1.transcription and promote mitochondrial biogenesis and oxida-
tive phosphorylation in skeletal muscle.
During our exploration into the metabolic regulation of skeletal
muscle, we were intrigued to discover through chromatin immu-
noprecipitation sequencing (ChIP-seq) that MyoD binds to
numerous metabolic genes, including PGC-1b, but surprisingly
not PGC-1a. Through genetic manipulation of cultured muscle
cells and in vivo skeletal muscle, we uncovered that MyoD is a
regulator of oxidative muscle metabolism. Furthermore, we
reveal that MyoD regulation of metabolic genes such as PGC-
1b depends on cooperative activity with the alternative NF-kB
transcription factor RelB via chromatin remodeling. These data
thereby establish a regulatory link between MyoD, alternative
NF-kB, and mitochondrial oxidative metabolism.
RESULTS
MyoD Binds to a Network of Metabolic Genes
MyoD is a master regulator of muscle differentiation with several
important functions attributed to its target genes. Most notably,
MyoD regulates expression of myofibrillar genes that form
the sarcomere and facilitate muscle contraction. We were inter-
ested in what other cellular processes could be regulated by
MyoD. To explore this, we analyzed MyoD ChIP-seq data from
murine C2C12 myotubes. As expected, MyoD binding was
strongly associated with muscle contraction and differentiation
(Figure S1A).
However, many of the top biological processes associated
with MyoD binding were unexpectedly related to metabolism,
an intriguing finding since the regulation of muscle metabolism
has not been directly linked to MyoD (Figure 1A). Gene ontology
(GO) categories related to oxidative metabolism, including mito-
chondrial biogenesis, fatty acid metabolism, and the TCA cycle,Cellwere prevalent throughout the analysis
(Figure 1B). The wide range of functions
found by GO analysis was supported by
our finding that MyoD binds to specific
target genes implicated in mitochondrial
biogenesis, fatty acid oxidation, mito-
chondrial fission, electron transport, and
mitochondrial protein translation (Fig-
ure 1C). As a reference and positive con-
trol, MyoD was also found to bind to themyogenin gene (Figure S1B). These results imply that MyoD
directly regulates a broad collection of metabolic genes involved
in multiple aspects of mitochondrial respiration.
MyoD Regulates Skeletal Muscle Oxidative Metabolism
To examine whether MyoD is a bona fide regulator of oxidative
metabolism, we first generated a C2C12 myoblast cell line con-
taining a doxycycline (dox)-inducible small hairpin RNA (shRNA)
targeting MyoD (TRIPZ-shMyoD). When C2C12 TRIPZ-shMyoD
cells were differentiated intomaturemyotubes and subsequently
treated with dox, MyoD levels declined over time (Figure 2A). In
contrast, no change in MyoD expression was observed in a
separately generated C2C12 cell line expressing a dox-inducible
scrambled shRNA (TRIPZ-shControl). To assess whether MyoD
knockdown perturbed the metabolism of these myotubes, we
analyzed oxygen consumption rate (OCR) as a measure of
aerobic respiration using the Seahorse Bioscience XFe24 (as
illustrated in Figure 2B). We found that C2C12 TRIPZ-shMyoD
myotubes treated with dox had a significantly lower OCR than
dox-treated TRIPZ-shControl myotubes (Figure 2C). Further-
more, treatment of these myotubes with the mitochondrial
uncoupling agent carbonyl cyanide p-trifluoromethoxyphenylhy-
drazone (FCCP), which producesmaximal oxygen consumption,
revealed an even greater difference in OCR between control and
shMyoD myotubes (Figure 2C). These results suggested that
MyoD is required to maintain mitochondrial respiratory capacity.
Significantly, the reducedOCR of TRIPZ-shMyoDmyotubeswas
associated with reduced ATP content, indicating the functional
importance of this decreased respiration (Figure S2A).
To better understand the role of MyoD in mitochondrial meta-
bolism, we measured TCA cycle activity and fatty acid b-oxida-
tion in dox-treated C2C12 TRIPZ-shControl and TRIPZ-shMyoD
myotubes by using radiolabeled substrates [2-14C] pyruvate andReports 17, 514–526, October 4, 2016 515
[9,10-3H] palmitic acid (Wang et al., 2011) (illustrated in Figures
2D and 2E). Compared to control myotubes, silencing MyoD
reduced both TCA cycle activity and fatty acid b-oxidation (Fig-
ures 2D and 2E). These results, along with the OCR analyses,
support that MyoD is required to maintain normal mitochondrial
metabolism in skeletal muscle.
To assess the metabolic significance of MyoD in vivo, we
adapted the Seahorse XFe24 to monitor metabolism of intact,
non-permeabilized muscle tissue (Figure 2B). To test the validity
of using this platform in measuring muscle tissue respiration, we
first measured basal OCR from tibialis anterior (TA) muscles.
Following the addition of titrating concentrations of FCCP, we
observed that OCR values were stimulated (Figure S2B), as
would be expected from a mitochondrial uncoupling agent. To
then confirm that the Seahorse platform could effectively
contrast OCR between intact muscle tissues with known differ-
ences in oxidative capacity, we tested this assay on slow twitch
soleus muscles in comparison to fast twitch extensor digitorum
longus (EDL) muscles. As anticipated, OCR values were higher
in the more oxidative soleus muscle (Figure S2C). In addition,
FCCP treatment effectively stimulated OCR of both soleus and
EDL muscles (Figure S2C). These OCR measurements from tis-
sues were performed on a multi-well plate, which allowed for
simultaneous readings from 3 EDL muscles and 3 soleus mus-
cles, divided into 10 total tissue sections per muscle group.
Thus, these results demonstrate that the Seahorse XFe24 plat-
form could reliably be used to robustly measure and contrast
the respiration of intact skeletal muscle tissue.
In an effort to identify if MyoD has a functional significance in
adult muscle, we examined TA muscles of MyoD/ mice and
found that the lack of MyoD was associated with reduced basal
OCR compared towild-type littermates (Figure 2F). Furthermore,
stimulation of these tissues with FCCP revealed an accentuated
difference in maximal OCR, indicating reduced mitochondrial
respiration capacity in MyoD/ muscles. To circumvent poten-
tial metabolic differences due to the absence of MyoD during
embryogenesis and neonatal muscle development in MyoD/
mice, we electroporated adult wild-type murine TA muscle with
either a pGIPZ plasmid constitutively expressing an shRNA tar-
geting MyoD (pGIPZ-shMyoD) or a pGIPZ control plasmid. After
a 4-week post-transfection period, we observed a fiber transfec-
tion efficiency of nearly 60% (Figure S2D). Western blot analysis
showed that efficient knockdown of MyoD corresponded with
significantly lower basal and maximal OCR (Figure 2G). As an
additional functional endpoint, we assessed the enzymatic activ-
ity of citrate synthase, a critical component of the TCA cycle.
Consistent with the TCA cycle metabolic activity measured in
C2C12myotubes silenced forMyoD (Figure 2D), analysis of elec-
troporated tissues depleted of MyoD revealed significantly less
citrate synthase activity (Figure 2H). Furthermore, electropora-
tion of pGIPZ-shMyoD in TA muscle led to a pronounced reduc-
tion in the mRNA or protein expression of mitochondrial genes,
including ATP synthase lipid-binding protein (ATP5g), cyto-
chrome c oxidase subunit Va (COX5a), cytochrome c (Cyto C),
mitochondrially encoded cytochrome c oxidase I (MTCO1),
NADH dehydrogenase-ubiquinone 30 kDa subunit (NDUFS3),
succinate dehydrogenase complex subunit A flavoprotein
(SDHA), and ubiquinol-cytochrome c reductase core protein I516 Cell Reports 17, 514–526, October 4, 2016(UQCRC1) (Figures 2I and S2E). Such differences in OCR and
mitochondrial gene products strongly support that MyoD func-
tions in skeletal muscle as a regulator of mitochondrial biogen-
esis and oxidative metabolism.
MyoD Binds to the PGC-1b Gene
During muscle differentiation, our findings showed that respira-
tion increases along with PGC-1b gene expression and to a
lesser extent PGC-1a gene expression (Figures 3A and 3B). To
gain insight into the mechanism by which MyoD directly regu-
lates oxidative metabolism, we examined ChIP-seq data of
C2C12 cells at the PGC-1b and PGC-1a gene loci, since these
genes are both established master regulators of mitochondrial
biogenesis (Finck and Kelly, 2006). In C2C12 myoblasts, MyoD
binds multiple sites along the PGC-1b gene with additional
peaks bound in differentiated myotubes (Figure 3C). This was
in sharp contrast to the PGC-1a gene, which surprisingly
showed little to no evidence of MyoD binding in both myoblasts
and myotubes (Figure S3).
Further ChIP-seq analysis of the PGC-1a gene locus re-
vealed that RNA polymerase II (Pol II) binding was absent in
myoblasts and myotubes, suggesting that differentiation is
not sufficient to induce PGC-1a transcription (Figure S3). Addi-
tional inquiry revealed the combined presence of histone marks
H3K4me3 and H3K27me3 in myotubes, indicative of a poised,
yet transcriptionally suppressed, bivalent gene (Figure S3).
Interestingly, H3K27me3 is not present at the PGC-1a locus
in myoblasts, suggesting this bivalent chromatin structure
uniquely regulates the induction of PGC-1a expression in differ-
entiated muscle. Consistent with this, a repressive H3K27me3
mark was also found on the PGC-1a gene of myotubes when
an independent ChIP-seq dataset was used (accession number
GEO: GSM818949). In sharp contrast, the PGC-1b gene had
substantially more Pol II binding across its gene locus,
H3K4me3 at its promoter, and an absence of H3K27me3, all
indicative of a transcriptionally active gene in myotubes (Fig-
ure S4A). These results highlight distinctions in the transcrip-
tional regulation of these co-activators during skeletal muscle
differentiation.
Given thatMyoDbinding increases at thePGC-1b locus during
muscle differentiation, coincident with increased PGC-1b ex-
pression, we sought to determine whether MyoD directly regu-
lates PGC-1b transcription. We began by validating the MyoD
ChIP-seq data with a series of ChIP reactions to assess MyoD
binding during C2C12 differentiation. Using the myogenin pro-
moter as a positive control for MyoD binding, results confirmed
that MyoD occupies multiple sites along the first two introns of
the PGC-1b gene (Figure 3D). Although MyoD was bound to
some of these sites with varying intensities in myoblasts, the
binding at sites 2, 9, and 12 significantly increased upon differen-
tiation, coincident with increased PGC-1b transcription. These
results were confirmed in primary muscle cells where, similar
to C2C12 cells, MyoD binding increased during myogenesis
(Figure S4B). MyoD binding at these three sites was then con-
firmed in vivo. ChIP assays in adult TA muscle tissue demon-
strated that MyoD was significantly bound at sites 2, 9, and 12
of the PGC-1b gene locus in mature muscles (Figure 3E). The
binding of MyoD to the myogenin promoter was used as a
Figure 2. MyoD Regulates Skeletal Muscle Oxidative Metabolism
(A) C2C12 cells containing a stable, dox-inducible shRNA targeting MyoD or dox-inducible scrambled shRNA were differentiated for 4 days and subsequently
treated with 2 mg/mL dox for 3 days. MyoD expression was assessed by western blot.
(B) Diagram of Seahorse analysis for C2C12 myotubes or muscle tissue.
(C) C2C12 TRIPZ-shControl and TRIPZ-shMyoDmyotubes were treated with dox for 3 days. Basal OCRmeasurements were immediately followed by addition of
FCCP and measurement of maximal OCR (n = 10 per cell line).
(D) C2C12 TRIPZ myotubes treated with dox were provided with [2-14C] pyruvate, and the resulting 14CO2 was measured as an indicator of TCA cycle activity
(n = 3 per cell line).
(E) Similarly, TRIPZ myotubes treated with dox were provided with [9,10-3H] palmitic acid, and the resulting metabolized 3H2O was measured as an indicator of
fatty acid b-oxidation (n = 3 per cell line).
(F) Basal and maximal OCRs were measured from TA muscles of 12-week-old MyoD/ mice and wild-type littermates using the Seahorse XFe24. Values are
normalized to dry tissue weight (n = 9 samples per condition from 6 total tissues).
(legend continued on next page)
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positive control for primary myotubes as well as TA muscles.
Together, these results demonstrate that MyoD binding to the
PGC-1b gene increases during myogenesis at three particular
likely enhancer sites and remains bound in adult skeletal muscle.
MyoD Is a Direct Regulator of PGC-1b Transcription
To understand whether MyoD is important for promoting PGC-
1b transcription, we measured PGC-1b expression in MyoD/
mice. Compared to wild-type littermates, both PGC-1b mRNA
and protein were lower in MyoD/ TA muscles (Figures 4A
and 4B). This difference was not a developmental characteristic
of theMyoD/mice since a similar reduction ofPGC-1b expres-
sion was observed following the knockdown of MyoD in adult
wild-type TA muscles (Figures 4C and 4D).
We then wanted to determine whether the positive correlation
between MyoD and PGC-1b expression is due specifically to
MyoD binding on the PGC-1b gene. We utilized a CRISPR/
Cas9 genome editing strategy to remove a 150-bp region of
the PGC-1b gene containing MyoD site 9 (DMyoD9CRISPR)
in C2C12 cells (Figure 4E). ChIP analysis confirmed that
DMyoD9CRISPR led to the elimination of MyoD binding at the
site 9 locus, while binding at sites 2 and 12 was unaffected (Fig-
ure 4F). Significantly, MyoD binding at the myogenin promoter
was also not affected in C2C12 DMyoD9CRISPR myotubes (Fig-
ure S5A), indicating that this genomic deletion did not impair
MyoD binding at a known MyoD target gene besides PGC-1b.
Compared to control C2C12 myotubes, DMyoD9CRISPR myo-
tubes expressed significantly less PGC-1b mRNA and protein
(Figures 4G and 4H). Furthermore, ChIP experiments detected
significantly less Pol II phospho Ser2 (P-Pol II) on the PGC-1b
gene locus of DMyoD9CRISPR myotubes (Figure 4I). Collectively,
these data suggest that MyoD regulates PGC-1b transcription
through direct DNA binding.
MyoD and Alternative NF-kB Signaling Cooperatively
Regulate PGC-1b
Our previous findings demonstrated that PGC-1b is transcrip-
tionally regulated by the alternative signaling pathway of NF-kB
(Bakkar et al., 2012). Specifically, this occurs through two RelB
binding sites located in intron 1 of PGC-1b approximately 40
and 65 kb downstream from the transcriptional start site (Fig-
ure 5A). Consistent with this binding and the role of PGC-1b
in the regulation of oxidative phosphorylation, TA muscles
from adult RelB/ mice consumed significantly less oxygen
compared to TA muscles from wild-type littermates (Figure 5B).
Combined with our current results with MyoD, these findings
suggested that the regulation of muscle oxidative metabolic ca-
pacity by RelB and MyoD might be linked through their shared
regulation of PGC-1b. To gain insight into this regulation, we uti-
lized CRISPR/Cas9 in C2C12 cells to specifically delete a small
72-bp region at the first RelB binding site, 40 kb downstream(G) Basal andmaximal OCRsweremeasured on a singlemulti-well plate from 3 TA
with control pGIPZ. 10 tissue sections were analyzed per experimental condition
(H) TA muscles electroporated with pGIPZ-shMyoD or control pGIPZ were homog
per condition).
(I) TA muscles electroporated with pGIPZ-shMyoD or control pGIPZ were assess
*p < 0.05 relative to control. #, p < 0.05 relative to basal OCR. Error bars indicate
518 Cell Reports 17, 514–526, October 4, 2016of the PGC-1b transcriptional start site (DNF-kBCRISPR) (Fig-
ure 5C). Deleting this region of the PCG-1b gene eliminated
RelB binding (Figure 5D). Consistent with our previous findings,
C2C12 DNF-kBCRISPR myotubes expressed markedly less
PGC-1b than control myotubes (Figure 5E). Significantly, knock-
down ofMyoD in C2C12DNF-kBCRISPRmyotubes led to a further
reduction of PGC-1b expression (Figure 5E). Similar results with
respect to PGC-1b were obtained when alternative NF-kB
signaling was decreased through depletion of RelB or its up-
stream regulator IKKa by small interfering RNA (siRNA) knock-
down in combination with MyoD knockdown (Figures S6A and
S6B). These data support the notion that MyoD and alternative
NF-kB signaling exhibit additive activities in the regulation of
PGC-1b.
Given that MyoD and RelB bind to multiple sites on the PGC-
1b locus and have complementary functions, we then asked if
these transcription factors have a reciprocal effect on their
binding affinities to the PGC-1b gene. We began by deter-
mining whether alternative NF-kB signaling affects the ability
of MyoD to bind the PGC-1b gene. Indeed, knockdown of
either RelB or IKKa by siRNA restricted MyoD binding to multi-
ple sites on the PGC-1b gene (Figures S6C and S6D). MyoD
binding at the PGC-1b locus was also lower in primary myo-
tubes as well as TA muscle tissues from RelB/ compared
to RelB+/+ mice (Figures S6E and 5F). Together, these data
indicate that the alternative signaling pathway of NF-kB pro-
motes MyoD binding to the PGC-1b gene. To determine
whether the ability of RelB to impact MyoD binding was directly
due to its own binding on the PGC-1b gene, we performed
MyoD ChIP experiments on C2C12 DNF-kBCRISPR myotubes.
Impressively, MyoD binding to PGC-1b was profoundly
reduced by the selective removal of the local RelB binding
site (Figure 5G).
We then used C2C12 DMyoD9CRISPR myotubes to examine
whether the specific removal of the MyoD enhancer binding
site 9 of the PGC-1b gene could reciprocally affect RelB binding.
Results showed that C2C12 DMyoD9CRISPR myotubes had
dramatically less RelB binding on the PGC-1b gene compared
to control myotubes (Figure 5H). Therefore, regulation of PGC-
1b transcription is dependent on the mutual binding of MyoD
and RelB to the PGC-1b gene.
Given that MyoD and RelB binding sites on the PGC-1b gene
locus are not located in close proximity to one another (Fig-
ure 5A), we asked whether their ability to influence each other’s
binding activity involves chromatin remodeling. To test this
notion, nuclease accessibility assays were performed. Data re-
vealed that the PvuII restriction site adjacent to MyoD binding
site 9 on the PGC-1b gene became more susceptible to diges-
tion upon myoblast differentiation (Figure 5I), consistent with a
more transcriptionally active gene. However, deletion of MyoD
binding at site 9 of PGC-1b resulted in less PvuII digestion,muscles electroporatedwith pGIPZ-shMyoD and 3 TAmuscles electroporated
. Knockdown was assessed by western blot.
enized and lysate was used to measure citrate synthase activity (n = 3 muscles
ed by western blot.
mean ± SEM. See also Figure S2.
Figure 3. MyoD Binds to the PGC-1b Gene
(A) OCR was measured in C2C12 myoblasts and 4-day differentiated myotubes. Values are normalized to myonuclei number (n = 10 per condition).
(B) mRNA was extracted from C2C12 myoblasts and myotubes and quantitated by qRT-PCR (n = 3 per condition).
(C) Schematic representation of the PGC-1b gene locus showing exon-intron borders and the size of intron 1 compared to the entire gene. MyoD and Pol II ChIP-
seq data from C2C12 myoblasts and myotubes are aligned to the gene schematic.
(D) MyoD ChIP assays on C2C12 myoblasts and myotubes were performed at the myogenin promoter as a positive control and the indicated sites along the
PGC-1b gene (n = 3 per condition).
(E) MyoD ChIP assays were performed on 6-week-old murine TA muscles, with liver as a negative control (n = 3 per condition).
*p < 0.05. Error bars indicate mean ± SEM. See also Figures S3 and S4.suggesting more restricted and condensed chromatin com-
pared to control myotubes (Figure 5J). Likewise, a similar
reduction in chromatin accessibility was observed in C2C12DNF-kBCRISPR myotubes (Figure 5K). Together, our results
show that PGC-1b transcription is regulated by the cooperative
binding of MyoD and RelB to the PGC-1b gene.Cell Reports 17, 514–526, October 4, 2016 519
Figure 4. MyoD Is a Direct Regulator of PGC-1b Transcription
(A) mRNA was extracted and quantitated from TA muscles of MyoD+/+ and MyoD/ mice (n = 3 per condition).
(B) Protein extracts from TA muscles of MyoD+/+ and MyoD/ mice were analyzed by western blot.
(C) TA muscles from 8-week-old wild-type mice were electroporated with pGIPZ-shMyoD in one leg and pGIPZ control in the other leg. RNA was extracted after
4 weeks and analyzed by qRT-PCR. Data are paired for each mouse, with expression from knockdown in each pGIPZ-shMyoD treated TA muscle compared
relative to the control of the same mouse (n = 3 muscles per condition).
(D) Protein extracts from TA muscles electroporated with control pGIPZ or pGIPZ-shMyoD were assessed by western blot.
(E) PCR of C2C12 wild-type and DMyoD9CRISPR cells demonstrating the deletion of 150 bp at the MyoD binding site 9 locus on the PGC-1b gene.
(F) MyoD ChIP at the indicated sites on the PGC-1b gene comparing C2C12 control and DMyoD9CRISPR myotubes (n = 3 per condition).
(G) RNA was extracted from C2C12 control and DMyoD9CRISPR myotubes and analyzed by qRT-PCR (n = 3 per condition).
(H) Protein from C2C12 control and DMyoD9CRISPR myotubes was analyzed by western blot.
(I) P-Pol II ChIP was performed on C2C12 control and DMyoD9CRISPR myotubes (n = 3 per condition).
*p < 0.05. Error bars indicate mean ± SEM. See also Figure S5.MyoD Regulates Oxidative Metabolism through Multiple
Gene Targets
ChIP-seq results from Figure 1 showed that MyoD binds to mul-
tiplemetabolic genes, suggesting that its regulation of adult skel-
etal muscle oxidative metabolism extends beyond PGC-1b. We
tested this notion in vivo by knocking down expression of PGC-
1b alone,MyoD alone, orPGC-1b together withMyoD in TAmus-
cles (Figure 6A). Consistent with PGC-1b being an important
regulator of muscle metabolic homeostasis (Gali Ramamoorthy
et al., 2015), PGC-1b knockdown alone was sufficient to reduce
muscle OCR and expression of several mitochondrial genes (Fig-
ures 6B and 6C). In comparison, the knockdown of MyoD further520 Cell Reports 17, 514–526, October 4, 2016reduced both OCR and mitochondrial gene expression (Figures
6B and 6C), suggesting that PGC-1b is not the only transcrip-
tional target mediating the impact of MyoD on oxidative meta-
bolism. Additionally, the OCR of muscles with combined knock-
down of MyoD with PGC-1b was similar to MyoD knockdown
alone, supporting the notion that MyoD is an upstream regulator
of multiple genes involved in muscle oxidative metabolism.
MyoD and RelB Potentially Cooperate to Regulate
Numerous Mitochondrial Genes
Our findings that MyoD regulates metabolism through numerous
gene targets and cooperates with RelB to regulate PGC-1b led
Figure 5. MyoD and RelB Cooperatively Regulate PGC-1b Transcription
(A) Gene schematic of the PGC-1b gene visualized with MyoD ChIP-seq data. RelB binding sites are depicted within the first intron of the gene schematic. The
RelB site removed by CRISPR is indicated with an asterisk.
(B) OCR was measured from TA muscles of RelB+/+ and RelB/ littermates (n = 9 samples per condition from 6 total tissues).
(C) PCR comparing control and DNF-kBCRISPR myotubes demonstrating the 72 bp deletion at the RelB binding site.
(D) ChIP for RelB was performed on C2C12 control and DNF-kBCRISPR myotubes (n = 3 per condition).
(E) PGC-1bmRNA expression was compared between C2C12 control myotubes,DNF-kBCRISPR myotubes, and DNF-kBCRISPR myotubes transfected with MyoD
siRNA (n = 3 per condition).
(F) MyoD ChIP was performed on TA muscles of 6-week-old RelB+/+ and RelB/ littermates (n = 3 per condition).
(G) MyoD ChIP was performed on C2C12 control and DNF-kBCRISPR myotubes at the indicated sites along the PGC-1b gene (n = 3 per condition).
(H) RelB ChIP on the PGC-1b gene comparing C2C12 control and DMyoD9CRISPR myotubes (n = 3 per condition).
(I) PvuII nuclease accessibility was assessed in C2C12 myoblasts and myotubes at MyoD site 9 (n = 3 per condition).
(J) C2C12 control and DMyoD9CRISPR myotubes were compared using a PvuII nuclease accessibility assay (n = 3 per condition).
(K) Control and DNF-kBCRISPR myotubes were also assessed by PvuII nuclease accessibility at the PGC-1b gene (n = 3 per condition).
*p < 0.05 relative to control. #, p < 0.05 relative to DNF-kBCRISPR control myotubes. Error bars indicate mean ± SEM. See also Figure S6.
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Figure 6. MyoD Regulates Oxidative Meta-
bolism through Multiple Gene Targets
(A) TA muscles of 6-week-old mice were electro-
porated with either the pGIPZ control or pGIPZ-
shMyoD and control or PGC-1b siRNA. Knock-
down was assessed by western blot.
(B) Basal OCRs from electroporated TA muscles
described in (A) were determined using the
Seahorse XFe24 (n = 5 samples per condition from
12 total tissues).
(C) mRNA from TA described in (A) was analyzed
by qRT-PCR (n = 4 per condition)
*p < 0.05 relative to siControl pGIPZ. #, p < 0.05
relative to siPGC-1b pGIPZ. Error bars indicate
mean ± SEM.us to examine whether a similar cooperative mechanism exists
between these two transcription factors on other metabolic
genes. We therefore analyzed publicly available MyoD and RelB
ChIP-seq datasets to identify genes containing binding sites for
both transcription factors (MacQuarrie et al., 2013). Given that
RelB ChIP-seq data in skeletal muscle was not available, we uti-
lized humanRelBChIP-seq data from lymphoblastoid B cells and
pared down annotated peaks with microarray data identifying
RelB-regulated genes in mouse soleus muscle (Bakkar et al.,
2012; Zhao et al., 2014). This analysis revealed a total of 206
genes containing both human MyoD and RelB binding sites
(hMyoD, hRelB) whose functions are tightly linked to mitochon-
dria. A sampling of these genes included Nuclear Respiratory
Factor 1 (NRF1), Optic Atrophy 3 (OPA3), Peroxisome Prolifera-
tor-Activated Receptor Delta (PPARd), and Sirtuin 4 (SIRT4) (Fig-
ure7A). ThroughChIPassays forMyoDandRelBondifferentiated
human primarymyotubes, we confirmed thatMyoD andRelB co-
occupyNRF1,OPA3,PPARd, andSIRT4genes in skeletalmuscle
(Figure 7B). When we categorized the full collection of MyoD and
RelBco-occupiedgenes into functional classesusingToppGene,
we identified numerous biological processes and cellular compo-
nents strongly associated with mitochondrial biogenesis (Fig-
ure 7C). In sharp contrast, categories of muscle differentiation
and muscle contraction were not identified, suggesting that the
role for MyoD in regulating sarcomeric genes and genes involved
in myogenesis does not involve cooperation with alternative
NF-kB signaling (Figure 7C). The cooperative activity of MyoD
and alternative NF-kB instead targets a subset of genes focused
on the regulation of skeletal muscle oxidative metabolism.
DISCUSSION
MyoD is considered a master switch transcription factor with
critical roles in embryonic skeletal muscle development and522 Cell Reports 17, 514–526, October 4, 2016the injury repair process of postnatal
muscle (Cornelison et al., 2000; Megeney
et al., 1996; Rudnicki et al., 1993). In
contrast, the role of MyoD in maintaining
the homeostasis of adult skeletal muscle
has been less appreciated. Presumably,
the low basal expression of MyoD by
myofiber nuclei is sufficient to synthesizecontractile genes that form the sarcomere to generate force (Cao
et al., 2010).
Despite the integral role of energy metabolism in muscle func-
tion, myogenic transcription factors such as MyoD have not
been directly identified to regulate mitochondrial biogenesis,
although previous work describing the regulation of MyoD by
circadian rhythm genes did indirectly reveal a connection to
mitochondrial function (Zhang et al., 2012). However, the funda-
mental mechanisms by which MyoD directly targets metabolic
genes to maintain mitochondrial homeostasis have not been
established. Our current findings highlight a direct role for
MyoD in maintaining the oxidative metabolic capacity of homeo-
static adult skeletal muscle. Our data support that in adult
muscle, a basal level of MyoD expression is sufficient to tran-
scriptionally regulate a large cohort of genes involved in mito-
chondrial biogenesis and aerobic respiration. Thus, we propose
that MyoD is not only responsible for the generation of the
sarcomeric genes involved in contractile function, but it also sup-
ports the production of energy fueling adult skeletal muscle
contraction.
Our data additionally suggest that MyoD regulation of oxida-
tive metabolism occurs through the cooperation of the alterna-
tive NF-kB signaling pathway. For PGC-1b, this cooperativity
directly regulates transcription, and our bioinformatics analysis
revealed numerous other metabolic genes that appear to be
regulated by a similar mechanism. Of particular interest among
these genes is PPARd, whose function in regulating oxidative
metabolism in adult skeletal muscle is well established (Wang
et al., 2004). ChIP-seq analysis revealed that the PPARd gene
contains multiple MyoD binding peaks, which are juxtaposed
to RelB binding sites, similar to what we identified in the
PGC-1b gene locus. Another gene of interest was SIRT4, which
contained prominent overlappingMyoD andRelB binding peaks.
From the perspective of how MyoD and RelB binding sites are
Figure 7. MyoD and RelB May Coopera-
tively Regulate Numerous Mitochondrial
Genes
(A) ChIP-seq peaks for human MyoD and human
RelB are visualized with gene diagrams depicted
above peaks for NRF1, OPA3, PPARd, and SIRT4
genes.
(B) Differentiated human skeletal muscle cells
were analyzed by ChIP for MyoD and RelB binding
at the genes indicated. An asterisk indicates the
peak in (A) that was chosen to confirm binding by
ChIP (n = 3 per condition).
(C) Gene ontology analysis by ToppGene was
performed on genes common to hMyoDChIP-seq,
hRelB ChIP-seq, and microarray results from hu-
man myotube cultures, human lymphoblastoid
B cells, and murine wild-type versus RelB/ so-
leus muscle, respectively. Selected gene ontology
categories are presented with p values, with
accompanying non-significant categories listed
with n.s.positioned relative to each other on the different metabolic genes
that we identified, it will be interesting to determine in future
studies whether the cooperative functions between these tran-
scription factors are manifested through distinct regulatory
mechanisms.
One surprising result from the MyoD ChIP-seq dataset came
when we compared the PGC-1a and PGC-1b loci. Although
both are considered major regulators of mitochondrial biogen-
esis, ChIP-seq data at the PGC-1a locus showed little evidence
of MyoD binding in either myoblasts or myotubes. In addition,
ChIP-seq data in myotubes revealed the absence of Pol II, along
with the presence of repressive H3K27me3 marks, suggesting
that muscle differentiation is not sufficient to induce PGC-1a
transcription. In contrast, PGC-1b expression appears uniquely
associated with MyoD binding and muscle differentiation. These
data are also consistent with past studies showing that physio-
logical stimuli such as cold exposure and exercise induce
PGC-1a expression but not PGC-1b (Lin et al., 2002a; Morten-
sen et al., 2007). Thus, whereas PGC-1a regulates oxidative
metabolism of skeletal muscle in response to stress stimuli, it
is likely that the shift to oxidative phosphorylation during muscle
differentiation is controlled in part through PGC-1b, but not
PGC-1a.
Interestingly, we observed that knockdown of MyoD in adult
skeletal muscle decreased both PGC-1b and PGC-1a expres-Cellsion (Figures 4B and S5B). Since MyoD
binding sites were not identified in the
PGC-1a gene locus, this suggests that
MyoD is capable of regulating PGC-1a
either though an indirect mechanism or
through other transcriptional regulatory
domains that lie outside the regions
we explored. Another possibility is that
MyoD might impact the stability of the
PGC-1amRNA or protein. Although addi-
tional studies will be required to better
define the regulation of PGC-1a andPGC-1b co-activators during skeletal myogenesis and in adult
muscle, our results nevertheless add to the current understand-
ing of the regulatory mechanisms distinguishing these co-
activators and further define a role for PGC-1b in supporting
the fundamental metabolic requirements of skeletal muscle dur-
ing homeostasis.
In addition to muscle development and homeostasis, our
findings may also be applicable to our understanding of
rhabdomyosarcoma, which is the most common soft tissue
cancer in children. Rhabdomyosarcoma tumor cells express
MyoD, and the most prevalent theory regarding the develop-
ment and persistence of this cancer is that tumor cells
originating from skeletal muscle are unable to properly dif-
ferentiate (Keller and Guttridge, 2013; Tonin et al., 1991). This
disparity in part results from the inability of MyoD to properly
bind to and activate its target myogenic genes (MacQuarrie
et al., 2013). Interestingly, a study examining the metabolic
properties of human rhabdomyosarcoma tumors revealed a
dependence on glycolysis reminiscent of the Warburg effect
(Issaq et al., 2014). Given our current results, it is intriguing
to posit that loss of MyoD function not only compromises the
differentiation status of rhabdomyosarcoma tumor cells but
also contributes to the metabolic shift through the decline
of PGC-1b and potentially other regulators of oxidative
metabolism.Reports 17, 514–526, October 4, 2016 523
EXPERIMENTAL PROCEDURES
Materials
Antibodies against MyoD (sc-304), RelB (sc-226), and PGC-1b (sc-67286)
were obtained from Santa Cruz Biotechnology, PGC-1a (ab54481) from
Abcam, IKKa (IMG-136A) from Imgenex, phospho Ser2 Polymerase II
(MMS-129R) from BioLegend, Trimethyl-Histone H3 Lys4 (17-614) from
EMD Millipore, and a-tubulin (T5168) from Sigma-Aldrich. Antibodies against
Complex I subunit NDUFS3 (459130), Complex II subunit Fp (459200), and
Complex III subunit Core 1 (459140) were obtained from Invitrogen. siRNAs
for IKKa, RelB, MyoD, and PGC-1b were obtained from Thermo Scientific.
Basic human FGF (G5071) was purchased from Promega; insulin (I0516),
gelatin (G1393), doxycycline (D9891), FCCP (C2920), and hyaluronidase
(H4272) from Sigma-Aldrich; and collagenase P (11249002001) and dispase
(04942078001) from Roche. pGIPZ and pTRIPZ plasmids were obtained
from Thermo Scientific. pLenti-CMV-rtTA3-Blast (plasmid #w756-1) and
pX330-U6-Chimeric_BB-CBh-hSpCas9 (plasmid #42230) were obtained
through Addgene.
Cell Culture
C2C12 murine myoblasts were cultured in high-glucose DMEM containing
10% fetal bovine serum (FBS) and antibiotics as previously described (Gut-
tridge et al., 2000). Cells were transfected with Lipofectamine 2000 (Invitrogen,
11668-019) following the manufacturer’s instructions. C2C12 myoblasts were
differentiated in high-glucose DMEM supplemented with 2% horse serum,
100 ng/mL insulin, and antibiotics. Primary murine myoblasts were isolated
from embryonic day 2 neonates as previously described (Rando and Blau,
1994) and differentiated in DMEM supplemented with 10% FBS. Human pri-
mary skeletal muscle myoblasts were purchased from Lonza (CC-2580) and
cultured according to their recommended protocols.
Mice
Animals were housed in the animal facility at The Ohio State University
Comprehensive Cancer Center, fed a standard diet, and kept at constant tem-
perature and humidity. Treatment of mice was in accordance with the institu-
tional guidelines of the Institutional Animal Care and Use Committee.MyoD/
mice (stock no. 002523) were obtained from The Jackson Laboratory.
Bioinformatics
hMyoD rawdata were downloaded from a public database and aligned to hg19
using Bowtie 2. Only uniquely alignable reads were kept, and all duplicates
were removed. HOMER was used for peak calling, annotation, and visualiza-
tion. HOMER assigns peaks to the gene with the nearest transcriptional start
site. For ChIP-seq visualization, BED files were uploaded to the UCSC data-
base (Kent et al., 2002). hRelB peak files were provided by Zhao et al.
(2014). HOMER was used to annotate peaks and create a visualization file.
We then identified overlapping genes between these ChIP-seq datasets and
a previously published microarray dataset comparing wild-type and RelB/
soleus muscle (Bakkar et al., 2012). Functional categories for these genes
were identified using Toppgene. HOMER was used for annotation and gene
ontology analysis of MyoD ChIP-seq data derived from C2C12 myotubes.
Chromatin Immunoprecipitation
ChIP analysis of C2C12 cells and tissues was performed as previously
described with 2 mg antibody per sample (Bakkar et al., 2012). 8-week-old
mice were used for tissue ChIPs. Each ChIP assay included an IgG control
experiment in parallel. Results expressed as fold enrichment represent pull-
down of the experimental antibody relative to the pull-down of the IgG control.
Electroporation
6-week-old mice were first injected in the TA muscle with 15 mL of 2 mg/mL
hyaluronidase, which improves transfection efficiency (McMahon et al.,
2001). After 50 min, mice were then injected with 30 mg plasmid DNA or 5 mg
siRNA. Electroporation was performed using a BTX Electro Square Porator
ECM 830 at 100 V/cm. Mice were anesthetized with isoflurane throughout
the procedure.524 Cell Reports 17, 514–526, October 4, 2016Gene Expression Analysis
Total RNA was isolated using TRIZOL (Life Technologies, 15596081), followed
bycDNAsynthesiswithM-MLV reverse transcriptase (Invitrogen, 28025). Real-
time RT-PCR was performed using SYBR green (Roche, 04913914001). Sam-
ples were normalized using b-actin as a housekeeping gene.
Analysis of Mitochondria and Respiration
Seahorse XFe24 analysis of C2C12 cells to measure basal and maximal OCR
was performed as suggested by the manufacturer. Comparisons between
C2C12 myoblasts and myotubes were normalized to total myonuclei number.
Cellular ATP concentration was quantified in C2C12 cells using the CellTiter-
Glo Luminescent Cell Viability kit (Promega, G7570).
OCR of muscle tissue was measured using the Seahorse XF24 Islet Capture
Microplates (Seahorse Bioscience, 101122-100). Tissues were dissected into
1.5=mm cross-sections and incubated for 1 hr in DMEM supplemented with
10 mM glucose, 2 mM L-glutamine, and 1 mM sodium pyruvate. Basal OCR
measurements were obtained immediately prior to addition of FCCP.
Following OCR measurements, tissues were dried at 60C for 48 hr. All tissue
OCR measurements were then normalized to dry tissue weight.
Citrate synthase activity was measured from TA muscles 4 weeks after
electroporation with pGIPZ control or pGIPZ-shMyoD plasmid following the
protocol reported by Spinazzi et al. (Spinazzi et al., 2012). In brief, muscle
homogenate was incubated with Acetyl CoA, oxaloacetic acid, and DTNB, fol-
lowed by spectrophotometry measurements at 412 nm for 3 min.
Metabolic Flux Analysis
Fatty acid b-oxidation flux was determined by measuring the detritiation of
[9,10-3H]-palmitic acid (Buzzai et al., 2005; Moon and Rhead, 1987). C2C12
dox-treated TRIPZ-shMyoD or TRIPZ-shControl myotubes were suspended
in 0.5 mL fresh media. In parallel, a duplicate set of cells were pre-incubated
with 100 mM etomoxir (Sigma-Aldirch, E1905), an inhibitor of carnitine palmi-
toyltransferase I (CPT1), for 1 hr. The experiment was initiated by adding
3 mci [9,10-3H]-palmitic acid complexed to 5% BSA (lipids free; Sigma-
Aldrich), and 2 hr later, media was transferred to a 1.5-mL microcentrifuge
tube containing 50 mL 5N HCl. The tubes were then placed in 20 mL scintilla-
tion vials containing 0.5 mL water, with the vials capped and sealed. 3H2Owas
separated from non-metabolized [9,10-3H]-palmitic acid by evaporation diffu-
sion for 24 hr at room temperature. Mitochondria-dependent b-oxidation rate
was determined by the difference between the oxidation rate in the absence or
in the presence of CPT1 inhibitor.
TCA cycle flux was determined by the rate of 14CO2 released from [2-
14C]-
pyruvate (Willems et al., 1978). C2C12 dox-treated TRIPZ-shMyoD myotubes
or TRIPZ-shControl myotubes were suspended in 1 mL fresh media. To facil-
itate the collection of 14CO2, cells were dispensed into 7-mL glass vials
(Thermo, TS-13028), each containing a 0.5-mL PCR tube with 50 mL 0.2M
KOH glued to the sidewall. After adding 0.5 mci [2-14C]-pyruvate, the vials
were capped using a screw cap with rubber septum (Thermo, TS-12713).
The assay was stopped 2 hr later by injection of 100 mL 5N HCl, and the vials
were kept at room temperate overnight to trap the 14CO2. The 50 mL KOH in the
PCR tubes were then transferred to scintillation vials containing 10 mL scintil-
lation solution for counting. A cell-free sample containing 0.5 mci [2-14C]-pyru-
vate was included as background control.
CRISPR Design and Screening
Guide RNA sequences were identified using a publicly available resource
developed by Feng Zhang’s lab at Broad Institute of MIT and Harvard
(http://crispr.mit.edu/). Sequences 72 bp apart were identified on either side
of the NF-kB site located approximately 40 kb downstream from the transcrip-
tional start site. Similarly, sequences 150 bp apart were identified on either
side of MyoD site 9 of the PGC-1b gene. Sequences were then cloned into
the pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid and transfected into
C2C12 cells. Individual cell clones were grown and screened by PCR for the
specific deletion.
Nuclease Accessibility Assay
A restriction enzyme accessibility assay utilizing ligation-mediated PCR was
performed as previously described with the following modifications (Ohkawa
et al., 2012). Briefly, cells were collected and incubated on ice for 5 min in
cytoplasmic extract (CE) buffer (10 mM HEPES [pH 7.6], 60 mM KCl, 1 mM
EDTA) supplemented with 0.25% NP40. Isolated nuclei were then washed
with CE buffer and digested in NEB Buffer 3.1 and 0.2 U/mg PvuII for 8 min
at 37C. DNA from the reaction was purified with a QIAGEN DNeasy purifica-
tion kit. DNA was subsequently ligated and quantitated as previously
described.
Statistical Analysis
Quantitative data are presented as mean ± SEM. Comparisons between two
different conditions were assessed using two-tailed Student’s t test, and com-
parisons between four different conditions were analyzed using a two-way
ANOVA. Statistical significance was evaluated as p < 0.05.
ACCESSION NUMBERS
The NCBI GEO accession numbers for C2C12 myoblast and myotube ChIP-
seq datasets are GEO: GSE25549 and GEO: GSE49313. The accession
number for the reported human myotube MyoD ChIP-seq data is GEO:
GSM1218850. The accession number for the reported RelB ChIP-seq data
of the lymphoblastoid cell line GM12878 is GEO: GSM1329661.
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